Literature DB >> 28893087

Protocol Modification of Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome Study.

Scott C Woller1, Scott M Stevens1, David A Kaplan2, Matthew T Rondina2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28893087      PMCID： PMC6714642          DOI： 10.1177/1076029617729214

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN： 1076-0296            Impact factor:   2.389


× No keyword cloud information.
  1 in total

1.  Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS).

Authors:  Scott C Woller; Scott M Stevens; David A Kaplan; D Ware Branch; Valerie T Aston; Emily L Wilson; Heather M Gallo; Eric G Johnson; Matthew T Rondina; James F Lloyd; R Scott Evans; C Gregory Elliott
Journal:  Clin Appl Thromb Hemost       Date:  2015-11-12       Impact factor: 2.389
  1 in total
  11 in total

Review 1.  Anticoagulating patients with high-risk acquired thrombophilias.

Authors:  Leslie Skeith
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  Thrombosis and Anti-phospholipid Syndrome: a 5-Year Update on Treatment.

Authors:  Cecilia Beatrice Chighizola; Pier Luigi Meroni
Journal:  Curr Rheumatol Rep       Date:  2018-05-31       Impact factor: 4.592

3.  [Hot topic: direct oral anticoagulants (DOAC) in antiphospholipid syndrome?]

Authors:  C Specker; T Dörner; M Schneider
Journal:  Z Rheumatol       Date:  2019-08       Impact factor: 1.372

Review 4.  The digestive system involvement of antiphospholipid syndrome: pathophysiology, clinical characteristics, and treatment strategies.

Authors:  Jin Zhang; Cheng Li; Xiaorong Han; Zhongbo Chen; Binay Kumar Adhikari; Yinghui Wang; Yonggang Wang; Jian Sun
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

Review 5.  The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS.

Authors:  Thomas McDonnell; Chris Wincup; Ina Buchholz; Charis Pericleous; Ian Giles; Vera Ripoll; Hannah Cohen; Mihaela Delcea; Anisur Rahman
Journal:  Blood Rev       Date:  2019-08-16       Impact factor: 10.626

Review 6.  Updates in Cerebral Venous Thrombosis.

Authors:  Arshia Alimohammadi; Diana J Kim; Thalia S Field
Journal:  Curr Cardiol Rep       Date:  2022-01-13       Impact factor: 2.931

Review 7.  Management of cardiovascular disease in patients with systemic lupus erythematosus.

Authors:  Paramarjan Piranavan; Andras Perl
Journal:  Expert Opin Pharmacother       Date:  2020-06-08       Impact factor: 3.889

8.  Massive thrombosis and phlegmasia cerulea dolens while taking rivaroxaban: case report and review.

Authors:  Diego Chemello; Larissa Rosa; Amanda Faria de Araujo; Pedro Cargnelutti de Araujo; Luiz Carlos Carneiro Pereira; Suélen Feijó Hillesheim; Marco Aurélio Lumertz Saffi
Journal:  J Vasc Bras       Date:  2021-04-28

9.  Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.

Authors:  Malgorzata M Bala; Magdalena Celinska-Lowenhoff; Wojciech Szot; Agnieszka Padjas; Mateusz Kaczmarczyk; Mateusz J Swierz; Anetta Undas
Journal:  Cochrane Database Syst Rev       Date:  2020-10-12

10.  16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends.

Authors:  Hannah Cohen; Maria J Cuadrado; Doruk Erkan; Ali Duarte-Garcia; David A Isenberg; Jason S Knight; Thomas L Ortel; Anisur Rahman; Jane E Salmon; Maria G Tektonidou; David J Williams; Rohan Willis; Scott C Woller; Danieli Andrade
Journal:  Lupus       Date:  2020-10       Impact factor: 2.911
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.